Table 1. Cohort Demographic Information.
SD, standard deviation; n, number of participants; IQR, interquartile range.
| Characteristic | Nonpregnant | Pregnant | Lactating |
|---|---|---|---|
| Age, mean (SD) | 38.4 (8.3) | 34.1 (3.3) | 34.6 (2.6) |
| Sample n, post-prime | 13 | 64 | 28 |
| Sample n, post-boost | 14 | 36 | 13 |
| Matched n (both post-prime and post-boost) | 12 | 29 | 11 |
| Vaccine type post-prime | |||
| BNT162b2 | 6 | 32 | 15 |
| mRNA-1273 | 7 | 32 | 13 |
| Vaccine type post-boost | |||
| BNT162b2 | 8 | 17 | 5 |
| mRNA-1273 | 6 | 19 | 8 |
| Days from dose 1 to post-prime collection, median (IQR) | 28 (27–29) | 28 (22–29.5) | 28 (23–30) |
| Days from dose 1 to post-prime collection, median (IQR), BNT162b2 | 25.5 (23.25–27.75) | 22 (21–24.75) | 22.5 (21–26.5) |
| Days from dose 1 to post-prime collection, median (IQR), mRNA-1273 | 29 (28–29.25) | 29 (28–31) | 30 (28–34.5) |
| Days from dose 1 to post-boost collection, median (IQR) | 49 (47.25–51.5) | 49.5 (43.75–56.25) | 49 (43–49.5) |
| Days from dose 1 to post-boost collection, median (IQR), BNT162b2 | 51 (49–55) | 57 (50–58) | 55 (50–59) |
| Days from dose 1 to post-boost collection, median (IQR), mRNA-1273 | 45.5 (44–47.75) | 47.5 (43.25–49.75) | 44 (43–49) |
| Days from dose 2 to post-boost collection, median (IQR) | 26 (19–30.25) | 20 (15–31.75) | 21 (14–29) |
| Days from dose 2 to post-boost collection, median (IQR), BNT162b2 | 29.5 (27.5–33.5) | 34 (14.75–37) | 34 (29–34) |
| Days from dose 2 to post-boost collection, median (IQR), mRNA-1273 | 17.5 (14.5–19) | 17 (15–21) | 14.5 (14–18) |
| Gestational Age at post-prime, median (IQR) | - | 23.2 (16.3–32.1) | - |